W. Kannel and D. Mcgee, Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study, Diabetes Care, vol.2, issue.2, pp.120-126, 1979.
DOI : 10.2337/diacare.2.2.120

E. Turkbey, J. Backlund, S. Genuth, A. Jain, C. Miao et al., Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus, Circulation, vol.124, issue.16, pp.1241737-1746, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.022327

H. Hadi and J. Suwaidi, Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag, pp.853-876, 2007.

D. Tousoulis, A. Kampoli, and C. Stefanadis, Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives, Current Vascular Pharmacology, vol.10, issue.1, pp.19-32
DOI : 10.2174/157016112798829797

V. Dzau, Vascular Wall Renin-Angiotensin Pathway in Control of the Circulation, The American Journal of Medicine, vol.77, issue.4, pp.31-36, 1984.
DOI : 10.1016/S0002-9343(84)80035-2

A. Heagerty, C. Aalkjaer, S. Bund, N. Korsgaard, and M. Mulvany, Small artery structure in hypertension. Dual processes of remodeling and growth, Hypertension, vol.21, issue.4, pp.391-397, 1993.
DOI : 10.1161/01.HYP.21.4.391

R. Ross, The pathogenesis of atherosclerosis, N Engl J Med, issue.8, pp.314488-500, 1986.

B. Patel and A. Mehta, Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases, European Journal of Pharmacology, vol.697, issue.1-3, pp.1-31
DOI : 10.1016/j.ejphar.2012.09.034

B. Dahlof, R. Devereux, S. Kjeldsen, J. S. Beevers, G. De-faire et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, The Lancet, vol.359, issue.9311, pp.359995-1003, 2002.
DOI : 10.1016/S0140-6736(02)08089-3

S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators, N Engl J Med, vol.342, issue.3, pp.145-153, 2000.

L. Hein, G. Barsh, R. Pratt, V. Dzau, and B. Kobilka, Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice, Nature, vol.377, issue.6551, pp.744-747, 1995.
DOI : 10.1038/377744a0

H. Siragy, T. Inagami, T. Ichiki, and R. Carey, Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor, Proceedings of the National Academy of Sciences, vol.96, issue.11, pp.966506-6510, 1999.
DOI : 10.1073/pnas.96.11.6506

M. Barber, D. Sampey, and R. Widdop, AT2 Receptor Stimulation Enhances Antihypertensive Effect of AT1 Receptor Antagonist in Hypertensive Rats, Hypertension, vol.34, issue.5, pp.1112-1116, 1999.
DOI : 10.1161/01.HYP.34.5.1112

B. Gigante, O. Piras, D. Paolis, P. Porcellini, A. Natale et al., Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats, Journal of Hypertension, vol.16, issue.Supplement, pp.2039-2043, 1998.
DOI : 10.1097/00004872-199816121-00027

P. Gohlke, C. Pees, and T. Unger, AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism, Hypertension, vol.31, issue.1, pp.349-355, 1998.
DOI : 10.1161/01.HYP.31.1.349

J. Coleman, L. Krebs, T. Hamilton, B. Ong, K. Lawrence et al., Autoradiographic Identification of Kidney Angiotensin IV Binding Sites and Angiotensin IV-Induced Renal Cortical Blood Flow Changes in Rats, Peptides, vol.19, issue.2, pp.269-277, 1998.
DOI : 10.1016/S0196-9781(97)00291-X

E. Kramar, R. Krishnan, J. Harding, and J. Wright, Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow, Regulatory Peptides, vol.74, issue.2-3, pp.2-3185, 1998.
DOI : 10.1016/S0167-0115(98)00039-1

A. Vinh, R. Widdop, G. Drummond, and T. Gaspari, Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice, Cardiovascular Research, vol.77, issue.1, pp.178-187, 2008.
DOI : 10.1093/cvr/cvm021

A. Vinh, R. Widdop, S. Chai, and T. Gaspari, Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma, Atherosclerosis, vol.200, issue.1, pp.37-44, 2008.
DOI : 10.1016/j.atherosclerosis.2007.12.042

F. Dowell, D. Henrion, M. Duriez, and J. Michel, Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats, British Journal of Pharmacology, vol.265, issue.Suppl??ment, pp.341-346, 1996.
DOI : 10.1111/j.1476-5381.1996.tb15196.x

K. Retailleau, E. Belin-de-chantemele, S. Chanoine, A. Guihot, E. Vessieres et al., Reactive Oxygen Species and Cyclooxygenase 2-Derived Thromboxane A2 Reduce Angiotensin II Type 2 Receptor Vasorelaxation in Diabetic Rat Resistance Arteries, Hypertension, vol.55, issue.2, pp.339-344, 2010.
DOI : 10.1161/HYPERTENSIONAHA.109.140236

N. Clere, S. Faure, J. Helesbeux, O. Duval, and R. Andriantsitohaina, Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells, Carcinogenesis, vol.32, issue.3, pp.286-295, 2011.
DOI : 10.1093/carcin/bgq260

R. Natarajan, N. Gonzales, L. Xu, and J. Nadler, Vascular smooth muscle cells exhibit increased growth in response to elevated glucose, Biochemical and Biophysical Research Communications, vol.187, issue.1, pp.552-560, 1992.
DOI : 10.1016/S0006-291X(05)81529-3

C. Alipui, K. Ramos, T. Tenner, and . Jr, Alterations of rabbit aortic smooth muscle cell proliferation in diabetes mellitus, Cardiovascular Research, vol.27, issue.7, pp.1229-1232, 1993.
DOI : 10.1093/cvr/27.7.1229

M. Creager, T. Luscher, F. Cosentino, and J. Beckman, Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I, Circulation, vol.108, issue.12, pp.1527-1532, 2003.
DOI : 10.1161/01.CIR.0000091257.27563.32

A. Lerman and A. Zeiher, Endothelial Function: Cardiac Events, Circulation, vol.111, issue.3, pp.363-368, 2005.
DOI : 10.1161/01.CIR.0000153339.27064.14

M. Widlansky, N. Gokce, J. Keaney, and . Jr, The clinical implications of endothelial dysfunction, Journal of the American College of Cardiology, vol.42, issue.7, pp.1149-1160, 2003.
DOI : 10.1016/S0735-1097(03)00994-X

M. Cooper, J. Rumble, R. Komers, H. Du, K. Jandeleit et al., Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition, Diabetes, issue.10, pp.431221-1228, 1994.

M. Cooper, Pathogenesis, prevention, and treatment of diabetic nephropathy, The Lancet, vol.352, issue.9123, pp.213-219, 1998.
DOI : 10.1016/S0140-6736(98)01346-4

S. Faure, R. Chapot, D. Tallet, J. Javellaud, J. Achard et al., Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors, J Physiol Pharmacol, vol.57, issue.3, pp.329-342, 2006.

V. Tiyerili, C. Mueller, U. Becher, T. Czech, M. Van-eickels et al., Stimulation of the AT2 receptor reduced atherogenesis in ApoEAT1A(-/-) double knock out mice, J Mol Cell Cardiol, vol.2012, issue.523, pp.630-637

A. Koitka, Z. Cao, P. Koh, A. Watson, K. Sourris et al., Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes, Diabetologia, vol.355, issue.3, pp.584-592, 2010.
DOI : 10.1007/s00125-009-1619-x

M. Avila, J. Morgan, and X. Yan, Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure, J Biomed Biotechnol, 2011.

R. Widdop, E. Jones, R. Hannan, and T. Gaspari, receptors: cardiovascular hope or hype?, British Journal of Pharmacology, vol.125, issue.5, pp.809-824, 2003.
DOI : 10.1038/sj.bjp.0705448

D. You, L. Loufrani, C. Baron, B. Levy, and R. Widdop, Henrion D: High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats, Circulation, issue.8, pp.1111006-1011, 2005.

R. Touyz, D. Endemann, G. He, J. Li, and E. Schiffrin, Role of AT2 Receptors in Angiotensin II??Stimulated Contraction of Small Mesenteric Arteries in Young SHR, Hypertension, vol.33, issue.1, pp.366-372, 1999.
DOI : 10.1161/01.HYP.33.1.366

R. Sabuhi, Q. Ali, M. Asghar, N. Al-zamily, and T. Hussain, Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats, AJP: Renal Physiology, vol.300, issue.3, pp.700-706, 2011.
DOI : 10.1152/ajprenal.00616.2010

H. Siragy, The potential role of the angiotensin subtype 2 receptor in cardiovascular protection, Current Hypertension Reports, vol.262, issue.4, pp.260-262, 2009.
DOI : 10.1007/s11906-009-0044-3

U. Steckelings, L. Paulis, T. Unger, and M. Bader, Emerging drugs which target the renin???angiotensin???aldosterone system, Expert Opinion on Emerging Drugs, vol.12, issue.4, pp.619-630, 2011.
DOI : 10.1126/science.1192152

S. Foulquier, U. Steckelings, and T. Unger, Perspective: A tale of two receptors, Nature, vol.185, issue.7434, p.9
DOI : 10.1038/493S9a

U. Steckelings, M. Larhed, A. Hallberg, R. Widdop, E. Jones et al., Non-peptide AT2-receptor agonists, Current Opinion in Pharmacology, vol.11, issue.2, pp.187-192, 2011.
DOI : 10.1016/j.coph.2010.11.002

A. Albiston, S. Mcdowall, D. Matsacos, P. Sim, E. Clune et al., Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase, Journal of Biological Chemistry, vol.276, issue.52, pp.27648623-48626, 2001.
DOI : 10.1074/jbc.C100512200

P. Vanderheyden, From angiotensin IV binding site to AT4 receptor, Molecular and Cellular Endocrinology, vol.302, issue.2, pp.159-166, 2009.
DOI : 10.1016/j.mce.2008.11.015

A. Albiston, R. Fernando, S. Ye, G. Peck, and S. Chai, Alzheimer's, Angiotensin IV and an Aminopeptidase, Biological & Pharmaceutical Bulletin, vol.27, issue.6, pp.765-767, 2004.
DOI : 10.1248/bpb.27.765

A. Albiston, S. Diwakarla, R. Fernando, S. Mountford, H. Yeatman et al., Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers, British Journal of Pharmacology, vol.333, issue.1, pp.37-47, 2011.
DOI : 10.1111/j.1476-5381.2011.01402.x

S. Faure, A. Bureau, N. Oudart, J. Javellaud, A. Fournier et al., Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors, Journal of Hypertension, vol.26, issue.10, pp.262008-2015, 2008.
DOI : 10.1097/HJH.0b013e32830dd5ee

URL : https://hal.archives-ouvertes.fr/hal-00594043

V. Pham, A. Albiston, C. Downes, C. Wong, S. Diwakarla et al., Insulin-Regulated Aminopeptidase Deficiency Provides Protection against Ischemic Stroke in Mice, Journal of Neurotrauma, vol.29, issue.6, pp.291243-1248
DOI : 10.1089/neu.2011.1824